Biomarin Pharmaceut (BMRN) 100.25 $BMRN Conatus (CNAT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biomarin Pharmaceut (BMRN) 100.25 $BMRN

Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)

BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)

Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:51PM CDT
Pfizer (PFE), which is set to report second-quarter 2016 results on Aug 2, had delivered a positive earnings surprise of 21.82% last quarter. Will it beat estimates again?
BMRN: 100.25 (+0.83), PFE: 37.31 (+0.42), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)

SmarTrend Watching for Potential Pullback in Shares of BioMarin Pharmaceutical After 1.14% Gain
Comtex SmarTrend(R) - Thu Jul 28, 12:30PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $96.64 to a high of $99.50. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $98.71 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 100.25 (+0.83)

Covered Call reports for GoPro, American Airlines, BioMarin Pharmaceutical, Caterpillar Inc. and TASER International include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAL, BMRN, CAT, GPRO, and TASR.
GPRO: 12.94 (+0.30), BMRN: 100.25 (+0.83), AAL: 35.60 (+0.10), CAT: 81.95 (-0.81), TASR: 29.16 (+0.20)

BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 6.6%
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:15AM CDT
BioMarin Pharmaceutical Inc. (BMRN) shares rose almost 7% in the last trading session.
BMRN: 100.25 (+0.83), ANIP: 61.06 (+0.46)

FDA Accepts BLA for BioMarin's Cerliponase Alfa for CLN2 Disease, Form of Batten Disease
GlobeNewswire - Wed Jul 27, 5:01PM CDT
Potential First Treatment for Fatal, Rare, Brain Disease in Children
BMRN: 100.25 (+0.83)

BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress
GlobeNewswire - Wed Jul 27, 1:30PM CDT
6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7 patient above 10%
BMRN: 100.25 (+0.83)

Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 6:24AM CDT
Merck (MRK) had posted a positive earnings surprise in Q1. Will the stock deliver a positive surprise again this quarter?
BMRN: 100.25 (+0.83), MRK: 58.66 (unch), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)

ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 5:58AM CDT
Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
BMRN: 100.25 (+0.83), INCY: 90.00 (-0.21), AMGN: 174.16 (+2.13), ARIA: 9.71 (+0.20)

Micron, JC Penney, Seagate Technology, Amazon.com, and BioMarin Pharmaceutical and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Jul 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, BMRN, JCP, MU, and STX.
MU: 13.56 (-0.18), AMZN: 767.74 (+8.93), BMRN: 100.25 (+0.83), STX: 32.43 (+0.40), JCP: 9.71 (+0.05)

BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 5.58%
Comtex SmarTrend(R) - Fri Jul 15, 12:21PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $89.19 to a high of $94.00. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $89.98 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 100.25 (+0.83)

New Reports on Recent Market Movers BioMarin Pharmaceutical, SemiLEDs, Fitbit and EZCORP
ACCESSWIRE - Mon Jul 11, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / July 11, 2016 / Despite positive falling jobless claims, U.S. markets slumped Thursday alongside oil prices. The Dow Jones Industrial Average fell 0.14 percent to close at 17,892.89, while the S&P 500 Index declined 0.09 percent to close at 2,097.70. Oil prices declined 4.8 percent to settle near two-month lows after data showed a smaller-than-expected decline in inventories. The Energy Information Administration reported U.S. crude stockpiles decreased by 2.2 million barrels to 524.4 million for the week ended July 1st. Analysts had forecasted a decline of 2.3 million barrels, according to a poll by Reuters. On Wednesday, the American Petroleum Institute reported a decline of 6.7 million barrels.
FIT: 13.69 (+0.03), BMRN: 100.25 (+0.83), EZPW: 9.04 (-0.02), LEDS: 5.49 (-0.11)

Catabasis' DMD Drug in Phase II Open-Label Extension Study
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:28AM CDT
Catabasis (CATB) initiated an open-label extension for the phase II portion (Part B) of its MoveDMD study on edasalonexent for the treatment of DMD.
BMRN: 100.25 (+0.83), CATB: 4.08 (+0.21), GWPH: 96.11 (+1.79), SRPT: 25.91 (+0.63)

BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 7.81%
Comtex SmarTrend(R) - Thu Jul 07, 11:57AM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $86.14 to a high of $90.20. Yesterday, the shares gained 7.8%, which took the trading range above the 3-day high of $81.67 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 100.25 (+0.83)

BioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL
GlobeNewswire - Mon Jun 20, 3:35PM CDT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII International Congress of the World Federation of Hemophilia. The presentation will report interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia. BMN 270 has received orphan drug designation from the European Commission and U.S. Food and Drug Administration.
BMRN: 100.25 (+0.83)

The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 301.83 (+11.90), BMRN: 100.25 (+0.83), ALXN: 133.50 (+4.90), IBB: 294.07 (+4.63), REGN: 434.00 (+8.88)

4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 301.83 (+11.90), BMRN: 100.25 (+0.83), SRPT: 25.91 (+0.63), ALXN: 133.50 (+4.90), IBB: 294.07 (+4.63), REGN: 434.00 (+8.88)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 269

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
NaLA Pushes for Stronger Lifeline Fraud Measures

Updated Category News Views 89

Here's the thing about the Lifeline program: it's meant to be a lifeline, not a loophole for the crafty and unscrupulous. The National Lifeline Association (NaLA) is slamming the table, demanding that the Senate Commerce Committee put some real muscle into preventing fraud. Why the Urgency on Lifeline Fraud? NaLA’s got its sights on a more robust defensive line against...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 121

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Blueprint Strengthens Team with New Capital Markets Director

Updated Category News Views 114

Blueprint Bolsters Its Ranks Hiring Caitlin Novak as Managing Director marks a pivotal step for Blueprint Healthcare Real Estate Advisors. They aren't just swapping pawns; they're making a statement, beefing up their capital markets strategy with a heavy hitter seasoned in steering around fiscal pitfalls. Novak isn’t some rookie wet behind the ears—she's clocked more...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 162

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 186

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 66

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 77

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 202

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading

Top 5 Most Recently Viewed Articles

Future Tech Boosts Leadership with Mike Watkinson's Appointment

Updated Category News Views 156

Future Tech Welcomes New CRO to Boost Revenue Strategy Future Tech Enterprise, Inc., a reputable provider of technology solutions, has recently appointed Mike Watkinson as its new Chief Revenue Officer (CRO). In this role, he will be responsible for driving global revenue growth and improving sales strategies for the company. This appointment follows a recent expansion of...

Continue Reading
Supporting Careers of Migraine Sufferers: AbbVie Contest Open

Updated Category News Views 250

AbbVie Launches the Second Annual Career Catalyst Award for Migraine Sufferers AbbVie has opened the entries for the second annual AbbVie Migraine Career Catalyst Award™ contest, offering significant financial assistance to help winners achieve their career aspirations. This initiative is designed to empower individuals living with migraine in their professional...

Continue Reading
Shane Neil Joins Axis Insurance as Senior VP for Eastern Canada

Updated Category News Views 116

So, Axis Insurance shook things up back when they named Shane Neil as their Senior Vice President of Corporate Development for Eastern Canada. This guy's got over 20 years in the insurance game, having kicked off his career at Chubb and moving through some heavyweight roles since then. Traders were eyeing this appointment, knowing that big names can mean bigger moves in...

Continue Reading
Water Ways Technologies Reports Q2 2024 Financial Insights

Updated Category News Views 74

Water Ways Technologies Inc. Reports Q2 2024 Financial Results Water Ways Technologies Inc. (TSXV: WWT) has released its financial results for the second quarter of 2024. As a prominent provider of agricultural technology based in Israel, the company focuses on improving water irrigation solutions and is dedicated to fostering innovation in the agriculture industry....

Continue Reading
Celebrating Technological Excellence: Mats Karlsson's Acclaimed Achievement

Updated Category News Views 116

Icomera Honors CTO Mats Karlsson with the Polhem Prize 2025 Icomera is thrilled to announce that its Chief Technology Officer, Mats Karlsson, has been awarded the Polhem Prize 2025. This esteemed recognition is one of Sweden's highest honors for outstanding contributions to technological innovation, presented by the Swedish Association of Graduate Engineers. The...

Continue Reading